Question 3565 — pharmacy and medications

Summary

Mr. Jean Laussucq questions the Minister of Labor, Health, Solidarity and Families on the prolonged shortages of many essential medicines in France. These shortages concern crucial treatments for patients' health, worsening inequalities in access to care and endangering the lives of certain patients. It appears that these shortages are partly due to the priority given by certain laboratories pharmaceutical companies to export these drugs to countries where prices are higher. These practices, although economically advantageous for the companies concerned, raise the question of their responsibility with regard to the commitments linked to the marketing authorization (AMM) granted in France. Since 2021, the law has imposed reinforced obligations on marketing authorization holders (AMM) to prevent and manage medication shortages. In particular, they must implement shortage management plans (PGP), constituting safety stocks adapted to cover national needs and immediately notify any supply difficulty to the National Agency for the Safety of Medicines and Health Products (ANSM). He therefore wishes to know what measures it is considering to guarantee market supply as a priority. national in strategic medicines. He asks in particular whether price regulation tools, reinforced sanctions in the event of non-compliance with commitments or other incentive measures are being studied to quickly remedy this worrying situation.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.